ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
TransCode Therapeutics Inc

TransCode Therapeutics Inc (RNAZ)

0.3362
0.0082
(2.50%)
Cerrado 20 Noviembre 3:00PM
0.3362
0.00
( 0.00% )
Pre Mercado: 3:01AM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
0.3362
Postura de Compra
0.305
Postura de Venta
0.37
Volume Operado de la Acción
1
0.00 Rango del Día 0.00
0.216 Rango de 52 semanas 18.664
Capitalización de Mercado [m]
Precio Anterior
0.3362
Precio de Apertura
-
Última hora de negociación
03:34:34
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,724,881
Acciones en circulación
17,265,658
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.32
Beneficio por acción (BPA)
-1.07
turnover
-
Beneficio neto
-18.55M

Acerca de TransCode Therapeutics Inc

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regre... TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
TransCode Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAZ. The last closing price for TransCode Therapeutics was US$0.34. Over the last year, TransCode Therapeutics shares have traded in a share price range of US$ 0.216 to US$ 18.664.

TransCode Therapeutics currently has 17,265,658 shares in issue. The market capitalisation of TransCode Therapeutics is US$5.80 million. TransCode Therapeutics has a price to earnings ratio (PE ratio) of -0.32.

RNAZ Últimas noticias

TransCode Therapeutics Open Letter to Shareholders

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear...

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

The clinical trial Safety Review Committee (SRC) approved opening of Cohort 2 after review of safety data from the three patients comprising Cohort 1No significant safety or dose limiting...

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

Patients currently remain on study for continued treatment with TTX-MC138  No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleotide conjugated to...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0311-8.467193030220.36730.38230.31442002990.33781093CS
4-0.3198-48.750.6560.69690.3134489220.4746579CS
120.058320.97876934150.27790.80.222617248810.48120183CS
26-0.8638-71.98333333331.21.990.21613233870.52688167CS
52-8.8638-96.34565217399.218.6640.21614827712.60123879CS
156-2175.6638-99.9845496324217625040.2161493047211.63349313CS
260-4799.6638-99.9929958333480056000.2161679169852.74521267CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WORXSCWorx Corporation
US$ 1.82
(85.71%)
4.29M
PETWag Group Company
US$ 0.3383
(61.02%)
6.33M
XTKGX3 Holdings Company Ltd
US$ 0.1359
(51.00%)
2.15M
CRKNCrown Electrokinetics Corporation
US$ 1.09
(38.73%)
1.6M
VEEAVeea Inc
US$ 3.57
(26.60%)
974.97k
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
PYXSPyxis Oncology Inc
US$ 2.31
(-39.53%)
50.75k
HSTMHealthStream Inc
US$ 20.00
(-36.10%)
102
CACCamden National Corporation
US$ 33.10
(-28.53%)
99
MPBMid Penn Bancorp Inc
US$ 23.205
(-26.22%)
101
PETWag Group Company
US$ 0.3383
(61.02%)
6.33M
WORXSCWorx Corporation
US$ 1.82
(85.71%)
4.29M
XTKGX3 Holdings Company Ltd
US$ 0.1359
(51.00%)
2.15M
CRKNCrown Electrokinetics Corporation
US$ 1.09
(38.73%)
1.6M
NVDANVIDIA Corporation
US$ 140.45
(-3.73%)
1.52M

RNAZ Discussion

Ver más
MartinLutherKing MartinLutherKing 6 horas hace
And insiders seem to stay away from RNAZ stock as from plague. I did not receive a single response to my 3 emails I sent to Tom and/or IR. Not even acknowledging them or any of my concerns. That is how much a shareholder means to the management. Just to take our money and to vote Yes to approve them using us the same toxic ways. The change is overdue.
👍️0
MartinLutherKing MartinLutherKing 6 horas hace
There are over 100 studies of the role of miR-10b in at least 18 cancer types over the last 15 years, including some with contributions from our co-founders, making it one of the most studied microRNAs. Studies have shown that an inhibition of miR-10b "prevents the onset of metastasis and eliminate existing metastases, even after treatment has been discontinued." Metastases are responsible for about 90% of all cancer deaths, due to a lack of therapeutics. In Phase 0, a microdose of TTX-MC138 reduced miR-10b by 66%, 24 hours after injection. In another study, MN-anti-miR10b decreased miR-10b by 90% in 24-48 hours, and a 99% downregulation was observed within two weeks. It seems as though this data is quick to ascertain. It's been over two months since the first Phase 1 patients were dosed with 0.4mg/kg of TTX-MC138.

How can the CEO say there can be no assurance that this data will be released?
👍️0
MetaMonster MetaMonster 13 horas hace
Come to the office Habibi, Fitzgerald it's been so long you've been hiding like a dirty rat scumbag bastard of the the earth you piece of shit
👍️0
MetaMonster MetaMonster 13 horas hace
Going to make sure an R/S up Fitzgerald ass rat bastard scumbag piece of shit of the earth,
👍️0
georgie18 georgie18 14 horas hace
You never know is right but always good to when an R/S is on the table...🥳
👍️0
MartinLutherKing MartinLutherKing 15 horas hace
Monster news can hit the wires A/H or tomorrow morning brothers be on the lookout …
👍️0
MartinLutherKing MartinLutherKing 15 horas hace
Texas cowboys can pull the trigger at any moment brother
👍️0
MartinLutherKing MartinLutherKing 15 horas hace
You never know when the texas rattle shake will strike timing is key
👍️0
georgie18 georgie18 15 horas hace
Did a search on XCUR and your RNAZ post came up...🥳...Don't know if you are aware...

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company:

Dear Shareholders,

At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below.

Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).

A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.

If our stock does not meet this Nasdaq requirement, and we do not have your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse effect on the value of our company and the value of your stock.

Our assessment boils down to this: your vote is your decision about whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.

TransCode’s management and directors are unanimously determined to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to implement this decision.

We call for your understanding and greatly appreciate your support.
👍️0
MartinLutherKing MartinLutherKing 17 horas hace
The texas rattle snake can strike anytime now… keep your eyes open
👍️0
MartinLutherKing MartinLutherKing 17 horas hace
Unless the texas rattle snake strikes fda fast track status for the terminally ill cancer patients
👍️0
tw0122 tw0122 17 horas hace
Technicals oversold look at XCUR today lol. Most penny bios are just daytrades then load them beat down for the biggest gains. Adding .32-.34 until technicals change. Still a chance it goes to .20s again. Anything possible 
👍️0
MartinLutherKing MartinLutherKing 17 horas hace
All holding, The well is dry
👍️0
Ms Labonte Ms Labonte 17 horas hace
Fill em bid$$ $weet$$ I got your back$$$$
👍️0
Ms Labonte Ms Labonte 17 horas hace
Partnership, merger, buyout, junkie$$$$ it’s coming in your face $weet$$$
👍️0
MartinLutherKing MartinLutherKing 17 horas hace
What do we do brothers , double down or… sell at a loss
👍️0
Ms Labonte Ms Labonte 17 horas hace
Fill em bid$$ $weet$$ the party is coming$$$
👍️0
Ms Labonte Ms Labonte 17 horas hace
Who will it be junkie$$$$
Roche. Sales from oncology drugs: $27.82 billion.
Bristol-Myers Squibb. Sales from oncology drugs: $14.71 billion. ...
Johnson & Johnson. Sales from oncology drugs: $14.31 billion. ...
Pfizer. Sales from oncology drugs: $14.03 billion. ...
AstraZeneca. ...
Merck & Co. ...
Novartis. ...
AbbVie. ...
👍️0
MartinLutherKing MartinLutherKing 2 días hace
It’s a nobel prize with zero value
👍️0
MartinLutherKing MartinLutherKing 2 días hace
This is a big slap in the face for all the scientific community’s hard work and dedication for the past 20 years,
👍️0
MartinLutherKing MartinLutherKing 2 días hace
A nobel prize cancer clinical trials with a 5 million dollar market capitalization congratulations to all longs
👍️0
tw0122 tw0122 2 días hace
Covered short Friday ready to go long some .32s -.34s added so far. When all looks like from and gloom the news eventually follows this month December next year ...its coming patience game now
👍️0
MartinLutherKing MartinLutherKing 3 días hace
Congrats to all of management, job well done flushing the nobel prize down the toilet
👍️0
MartinLutherKing MartinLutherKing 3 días hace
We should congratulate Zdravka Medarova
CSO at TransCode Therapeutics for a job well done,
https://informaconnect.com/rna-leaders-usa/speakers/zdravka-medarova/
👍️0
MartinLutherKing MartinLutherKing 3 días hace
A nobel prize winning technology gone down the drain. Congrats to all longs. congratulations to all of management for a job well done
👍️0
tapioca tapioca 5 días hace
Back to the .20’s next week?
I’ll probably risk another small buy soon and hope for a bounce.
👍️0
MetaMonster MetaMonster 5 días hace
Everyone is looking for the rat bastard CEO scam artist Fitzgerald, you want to sabotage the cure to cancer, hunting season is officially open for dirty rats bastards like you who screw investors all their careers while they fill up their pockets and pull the plug master CFO your time is coming you piece of shit for sabotaging the only hope for terminally ill cancer patients
👍️0
MetaMonster MetaMonster 6 días hace
(857) 837-3099 Answer the phone CEO Fitzgerald everyone wants a piece of you rat bastard,
👍️0
MetaMonster MetaMonster 6 días hace
Answer the phone bastard Fitzgerald Keep on hiding rat bastard Fitzgerald everyone is waiting for you piece of shit , the Crack pipe will end up in your ass bastard scumbag fraud artist junkie
👍️0
MetaMonster MetaMonster 6 días hace
The rat bastard mother fucker Fitzgerald fucked them all up the ass, There is a line up of investors waiting for him at both offices with proactive investors hunting him down
👍️0
MetaMonster MetaMonster 6 días hace
Tom Fitzgerald fucked everyone he knows including his mother, a true scam artist master CFO cooking the books so he can fuck everyone and everything. we all know your sabotage strategy to fill up your pockets and pull the plug on all mother fucker, come to the office Habibi bastard
👍️0
MartinLutherKing MartinLutherKing 6 días hace
H.C. Wainwright & Co. reiterates RNAZ as a Buy, and maintains its $3 PT.
3) A RS "will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024."
4) There are 11.24M warrants at $1.22, for a total of $13.7M in funding, and another 357K at $1.525 for $543.7K.
5) On Jan. 18, 2025, another batch of 500K warrants at $0.375 become exercisable for $187.5K in funding.
👍️0
MartinLutherKing MartinLutherKing 6 días hace
The "doctors" at RNAZ, along with their partners/MMs/friends/family, can turn this thing around without a ratification/RS/offering, or they can face delisting, bankruptcy or a buyout. If I were Tom, I'd be on the phone nonstop, or does he not know anyone who believes in them?
👍️0
MetaMonster MetaMonster 6 días hace
Shareholders want to make sure you get a baseball bat up the ass for your virtual video fucking investors all your career you mother fucker rat bastard scum of the earth
👍️0
MetaMonster MetaMonster 6 días hace
Come out of your rat hole Fitzgerald and face the shareholders waiting for you in front of the office you bastard, You like fucking investors all your career, now shareholders have bonus plan for you rat bastard mother fucker
👍️0
MetaMonster MetaMonster 6 días hace
Collapse this piece of garage so you can sabotage the cure to cancer, you can all burn in hell you bastards, Fitzgerald filled up his pockets and is ready to pull the plug on all
👍️0
MetaMonster MetaMonster 6 días hace
Let Fitzgerald and all his bastards lab rats pull the plug and burn this big piece of shit cancer hoax to the ground in hell where they all belong
👍️0
MetaMonster MetaMonster 6 días hace
Go Fitzgerald go bankrupt this piece of shit company funnel the rest of the money in your pockets and run for your life you dirty rat piece of shit bastard of the earth
👍️0
MetaMonster MetaMonster 6 días hace
The world knows your a crack head junkie bastard cook the books master CFO scam artist of the Nasdaq Fitzgerald, burn it to the ground in hell where you belong
👍️0
MetaMonster MetaMonster 6 días hace
The rat Fitzgerald needs more money for his crack pipe, the junkie rat scam fraudster stole his mom's purse at the rehab center,
👍️0
MetaMonster MetaMonster 6 días hace
Nope, the rat Fitzgerald and his lab rats are ready to sabotage and run this billion dollar company to the ground, cook the books with master rat bastard Fitzgerald expertise and pocket all investors money and sell patients under the table to big pharma for big cash under the table
👍️0
MartinLutherKing MartinLutherKing 6 días hace
ALL of our partnerships? What is BRAIN/Akribion paying us??? Can we learn who our "undisclosed" and "in discussion" partners are? Or, how about some secondary efficacy results from Ph1, or, heck, how about letting us know where PH0 results stand?
👍️0
Here Today Here Today 6 días hace
That's why I voted NO to all 3 proposals!!!

Management needs to be mindful of the money and work hard to get more - Not just reverse split every single time they deem necessary.
👍️0
MartinLutherKing MartinLutherKing 6 días hace
Management have no respect for shareholders and it shows,
👍️0
MartinLutherKing MartinLutherKing 6 días hace
From the boston ghetto, He needs to be thought a lesson
👍️0
MartinLutherKing MartinLutherKing 6 días hace
At the moment of glory.. they shatter everyone’s dream to the promise land, Not good ceo not good at all for you and your family
👍️0
MartinLutherKing MartinLutherKing 6 días hace
Produce or delist.. how many times do you have to take shareholders to the cleaners, An accountant by profession a specialist on how to cook the books. Shame on you
👍️0
MetaMonster MetaMonster 6 días hace
Could would should Fitzgerald strikes again, Go bankrupt pull the plug and collapse this empty shell to the ground in hell where he belongs
👍️0
MetaMonster MetaMonster 6 días hace
That's because Fitzgerald smokes the crack pipe with street hookers, a full blown crack head junkie bastard would screw your mom for a dollar, pull the plug and go fuck yourself you rat bastard
👍️0
MetaMonster MetaMonster 6 días hace
Fitzgerald the world knows your a piece of shit rat bastard that would would steal your mom's purse in rehab you fucken cunt
👍️0

Su Consulta Reciente

Delayed Upgrade Clock